Steph N
09-08-2004, 08:22 AM
For you gals who have to go off your Herceptin because the trial is over. There are also a lot of posts here about how to boost immune system. If this was available in the Northwest, I would like to have participated. Believing that some mushrooms do have an anticancer effect, I have eaten plenty of Shiitake and others since diagnosis 4 years ago! The results are a long way off, but I will be watching for them.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Phase I/II Study of Maitake Mushroom D-Fraction in Breast Cancer Patients
[Protocol 03-107]
--------------------------------------------------------------------------------
Back to Breast Cancer Clinical Trials
Full Title :
A PHASE I/II STUDY OF MAITAKE MD-FRACTION IN BREAST CANCER PATIENTS
Purpose :
The liquid concentrate from the Maitake mushroom is widely used with chemotherapy to treat breast cancer and other cancers in Asia. Although little is known about its mechanism of action, Maitake mushroom extract is thought to activate the immune system.
Laboratory studies show that Maitake extract can reduce the growth of cancer in animals. Because it may work through the immune system, some healthy people take Maitake extract as a dietary supplement in hopes that it will help them ward off colds and the flu.
Investigators at Memorial Sloan-Kettering Cancer Center, in collaboration with The New York Presbyterian Hospital-Weill Medical College of Cornell University, hope to determine whether Maitake extract has any side effects or toxicity, if it can stimulate the immune system, and whether increasing the dose of Maitake extract causes more stimulation of the immune system. The extract will be evaluated in women with breast cancer.
Eligibility :
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
Patients must have a confirmed diagnosis of stage II breast cancer that was surgically removed and treated with chemotherapy. At least 4 weeks must have passed since last receiving chemotherapy.
Patients must have experienced menopause (either naturally or as a result of treatment).
Patients must not have a history of autoimmune disease or allergy to mushrooms.
Patients must be age 18 or older.
For more information and to see if you are eligible for this study, please contact Terri Gray, Research Manager, at 212-639-3305, or Tina Chuck, Research Study Assistant, at 212-639-3243.
--------------------------------------------------------------------------------
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Phase I/II Study of Maitake Mushroom D-Fraction in Breast Cancer Patients
[Protocol 03-107]
--------------------------------------------------------------------------------
Back to Breast Cancer Clinical Trials
Full Title :
A PHASE I/II STUDY OF MAITAKE MD-FRACTION IN BREAST CANCER PATIENTS
Purpose :
The liquid concentrate from the Maitake mushroom is widely used with chemotherapy to treat breast cancer and other cancers in Asia. Although little is known about its mechanism of action, Maitake mushroom extract is thought to activate the immune system.
Laboratory studies show that Maitake extract can reduce the growth of cancer in animals. Because it may work through the immune system, some healthy people take Maitake extract as a dietary supplement in hopes that it will help them ward off colds and the flu.
Investigators at Memorial Sloan-Kettering Cancer Center, in collaboration with The New York Presbyterian Hospital-Weill Medical College of Cornell University, hope to determine whether Maitake extract has any side effects or toxicity, if it can stimulate the immune system, and whether increasing the dose of Maitake extract causes more stimulation of the immune system. The extract will be evaluated in women with breast cancer.
Eligibility :
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
Patients must have a confirmed diagnosis of stage II breast cancer that was surgically removed and treated with chemotherapy. At least 4 weeks must have passed since last receiving chemotherapy.
Patients must have experienced menopause (either naturally or as a result of treatment).
Patients must not have a history of autoimmune disease or allergy to mushrooms.
Patients must be age 18 or older.
For more information and to see if you are eligible for this study, please contact Terri Gray, Research Manager, at 212-639-3305, or Tina Chuck, Research Study Assistant, at 212-639-3243.
--------------------------------------------------------------------------------